The association between intensified medical treatment, time to surgery and ileocolic specimen length in Crohn's disease

Colorectal Disease

Volumn 19, Issue 6, 2017, Pages 551-558

  de Groof, E J ^a   Gardenbroek, T J ^a   Buskens, C J ^a   Tanis, P J ^a   Ponsioen, C Y ^a   D'Haens, G R A M ^a   Bemelman, W A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Crohn's disease; ileocolic resection; medical therapy

Indexed keywords

IMMUNOMODULATING AGENT; TUMOR NECROSIS FACTOR INHIBITOR; GASTROINTESTINAL AGENT; IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR;

ADULT; AGE; ARTICLE; COCHRANE-ARMITAGE TREND; COHORT ANALYSIS; COLON RESECTION; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROHN DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; ILEUM RESECTION; INTENSIVE CARE; INTESTINE FISTULA; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; POPULATION RESEARCH; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TIME TO SURGERY; TREND STUDY; ANTAGONISTS AND INHIBITORS; COLON; ILEUM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TIME TO TREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; COLECTOMY; COLON; COMBINED MODALITY THERAPY; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; ILEUM; IMMUNOLOGIC FACTORS; LINEAR MODELS; MALE; TIME-TO-TREATMENT; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 85020067761     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.13567     Document Type: Article

References (12)

1. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000; 231: 38–45.
2. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28–62.
3. Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979−2011. Gut 2014; 63: 1607–16.
4. de Groof EJ, Rossen NG, van Rhijn BD, et al. Burden of disease and increasing prevalence of inflammatory bowel disease in a population-based cohort in the Netherlands. Eur J Gastroenterol Hepatol 2016; 28: 1065–72.
5. Eshuis EJ, Bemelman WA, van Bodegraven AA, et al. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial). BMC Surg 2008; 8: 15.
6. Fu YT, Hong T, Round A, et al. Impact of medical therapy on patients with Crohn's disease requiring surgical resection. World J Gastroenterol 2014; 20: 11808–14.
7. Tielbeek JA, Lowenberg M, Bipat S, et al. Serial magnetic resonance imaging for monitoring medical therapy effects in Crohn's disease. Inflamm Bowel Dis 2013; 19: 1943–50.
8. Herrinton LJ, Liu L, Fireman B, et al. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998−2005. Gastroenterology 2009; 137: 502–11.
9. Jones DW, Finlayson SR. Trends in surgery for Crohn's disease in the era of infliximab. Ann Surg 2010; 252: 307–12.
10. El-Hussuna A, Theede K, Olaison G. Increased risk of post-operative complications in patients with Crohn's disease treated with anti-tumour necrosis factor alpha agents − a systematic review. Dan Med J 2014; 61: A4975.
11. Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011; 60: 930–6.
12. Ramadas AV, Gunesh S, Thomas GA, et al. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986−2003): a study of changes in medical treatment and surgical resection rates. Gut 2010; 59: 1200–6.